JP4276779B2 - 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 - Google Patents

注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 Download PDF

Info

Publication number
JP4276779B2
JP4276779B2 JP2000503842A JP2000503842A JP4276779B2 JP 4276779 B2 JP4276779 B2 JP 4276779B2 JP 2000503842 A JP2000503842 A JP 2000503842A JP 2000503842 A JP2000503842 A JP 2000503842A JP 4276779 B2 JP4276779 B2 JP 4276779B2
Authority
JP
Japan
Prior art keywords
carnitine
acid
alkanoyl
treatment
adhd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000503842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001510800A5 (https=
JP2001510800A (ja
Inventor
クラウディオ・カバッツァ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2001510800A publication Critical patent/JP2001510800A/ja
Publication of JP2001510800A5 publication Critical patent/JP2001510800A5/ja
Application granted granted Critical
Publication of JP4276779B2 publication Critical patent/JP4276779B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000503842A 1997-07-22 1998-07-08 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 Expired - Fee Related JP4276779B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/898,433 1997-07-22
US08/898,433 US5869528A (en) 1997-07-22 1997-07-22 Therapeutical method for the treatment of attention-deficit/hyperactive disorders
PCT/IT1998/000188 WO1999004785A1 (en) 1997-07-22 1998-07-08 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders

Publications (3)

Publication Number Publication Date
JP2001510800A JP2001510800A (ja) 2001-08-07
JP2001510800A5 JP2001510800A5 (https=) 2005-12-22
JP4276779B2 true JP4276779B2 (ja) 2009-06-10

Family

ID=25409451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000503842A Expired - Fee Related JP4276779B2 (ja) 1997-07-22 1998-07-08 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用

Country Status (12)

Country Link
US (1) US5869528A (https=)
EP (1) EP0998276B1 (https=)
JP (1) JP4276779B2 (https=)
KR (1) KR100530879B1 (https=)
AT (1) ATE290376T1 (https=)
AU (1) AU735697B2 (https=)
CA (1) CA2297153C (https=)
DE (1) DE69829290T2 (https=)
ES (1) ES2237842T3 (https=)
NZ (1) NZ501966A (https=)
PT (1) PT998276E (https=)
WO (1) WO1999004785A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DK0951909T4 (da) 1998-03-19 2011-01-24 Sigma Tau Ind Farmaceuti Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
US6204291B1 (en) 1998-06-26 2001-03-20 The Iams Company Process for promoting weight loss in overweight dogs
US6630159B2 (en) * 1999-02-23 2003-10-07 The Procter & Gamble Company Limiting weight gain of cats by feeding carbohydrate source that excludes rice
US7001618B1 (en) 1999-07-09 2006-02-21 The Iams Company Nutritional composition for weight management
WO2001028554A1 (en) * 1999-10-20 2001-04-26 Thomas Jefferson University Treatment of attention deficit disorder and impaired visual-spatial function with androgen
ITRM20010218A1 (it) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi
JP4812968B2 (ja) * 2001-06-06 2011-11-09 太陽化学株式会社 注意欠陥多動性障害改善用組成物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AU2016219070B2 (en) 2015-02-13 2020-06-11 Mars, Incorporated Pet food feeding system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Also Published As

Publication number Publication date
US5869528A (en) 1999-02-09
HK1028546A1 (en) 2001-02-23
KR20010022008A (ko) 2001-03-15
CA2297153C (en) 2007-07-03
WO1999004785A1 (en) 1999-02-04
EP0998276B1 (en) 2005-03-09
AU8240598A (en) 1999-02-16
ATE290376T1 (de) 2005-03-15
AU735697B2 (en) 2001-07-12
PT998276E (pt) 2005-06-30
ES2237842T3 (es) 2005-08-01
DE69829290D1 (de) 2005-04-14
CA2297153A1 (en) 1999-02-04
DE69829290T2 (de) 2006-04-13
NZ501966A (en) 2001-12-21
JP2001510800A (ja) 2001-08-07
KR100530879B1 (ko) 2005-11-23
EP0998276A1 (en) 2000-05-10

Similar Documents

Publication Publication Date Title
CH641673A5 (it) Composizione farmaceutica comprendente una acil-carnitina per il trattamento del rallentato metabolismo cerebrale.
Tabor et al. Corneal damage due to eye contact with chlorhexidine gluconate
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
Madhusoodanan et al. Clinical experience with quetiapine in elderly patients with psychotic disorders
Millikan et al. Clinical evaluation of ACTH and cortisone in myasthenia gravis
Starkstein et al. Apathy and depression following stroke
Knezevic et al. Neuroleptic malignant syndrome
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
TW202228697A (zh) 以CNS穿透性sGC刺激劑治療認知損傷
EP1535616A1 (en) Remedy for integration dysfunction syndrome
Banerjee Recovery from prolonged cerebral depression after fluvoxamine overdose
JPS584718A (ja) 新規適応症に用うる医薬製剤
Fann et al. Effect of antidepressant and antimanic drugs on amine uptake in man
Calne Parkinsonism—physiology and pharmacology
US8013016B2 (en) Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome
TWI883819B (zh) 組合物用於製備改善認知能力之藥物的用途
HK1028546B (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
EP0698390B1 (en) Use of bifemelane for the manufacture of a medicament for the treatment of hyperkinetic disorders
MXPA00000441A (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
JPWO2007072902A1 (ja) 急性期脳梗塞治療剤
CN120437129A (zh) 组合物在制备用于改善认知能力方面的药物中的用途
JP2005015417A (ja) 抗疲労組成物
Kudo Clinical effectiveness off KB-831 on depression with once or twice daily dosage regimen
JPH0881366A (ja) 多動性障害治療剤
JPS63145231A (ja) ステロイド化合物を含有する脳機能賦活剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090224

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090309

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120313

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees